Compare · NVO vs QUCY
NVO vs QUCY
Side-by-side comparison of Novo Nordisk A/S (NVO) and Mainz Biomed N.V. (QUCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and QUCY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 1826.7x QUCY ($95.1M).
- Over the past year, NVO is down 28.6% and QUCY is down 28.5% - QUCY leads by 0.1 points.
- QUCY has been more active in the news (8 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for QUCY).
- Company
- Novo Nordisk A/S
- Mainz Biomed N.V.
- Price
- -
- -
- Market cap
- $173.66B
- $95.1M
- 1M return
- -10.14%
- -22.83%
- 1Y return
- -28.57%
- -28.52%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 8
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest QUCY
- SEC Form 8-K filed by Mainz Biomed N.V.
- Quantum Cyber Appoints Major General (Ret.) Alberto C. Rosende to Board of Directors
- SEC Form 8-K filed by Mainz Biomed N.V.
- SEC Form 424B5 filed by Mainz Biomed N.V.
- Quantum Cyber Files Audited and Reviewed Financial Statements and Pro Forma Financial Information for Bridgeport Manufacturing Acquisition
- Amendment: Mainz Biomed N.V. filed SEC Form 8-K: Financial Statements and Exhibits
- Mainz Biomed N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Quantum Cyber Sharpens Strategic Focus to Quantum Navigation, Interceptor Drones, and U.S. Manufacturing, and Presents New Corporate Investor Presentation
- Quantum Cyber Acquires NVIDIA A100 AI Compute Cluster to Power Its Swarm Operating System
- Quantum Cyber Invites Qualified Foundries, and Prototype-Development Partners to Apply for Its Quantum-Photonic Antenna Manufacturing Program; Responses Due September 18, 2026